Cargando…

Clinical value of routine serum squamous cell carcinoma antigen in follow-up of patients with locally advanced cervical cancer treated with radiation or chemoradiation

OBJECTIVE: The objective of this study was to evaluate the clinical benefits of routine squamous cell carcinoma antigen (SCC-Ag) monitoring of patients with locally advanced cervical squamous cell carcinoma treated with radiation or chemoradiation. METHODS: A total of 53 patients with recurrent cerv...

Descripción completa

Detalles Bibliográficos
Autores principales: Oh, Jinju, Lee, Hyun Joo, Lee, Tae Sung, Kim, Ju Hyun, Koh, Suk Bong, Choi, Youn Seok
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Society of Obstetrics and Gynecology; Korean Society of Contraception and Reproductive Health; Korean Society of Gynecologic Endocrinology; Korean Society of Gynecologic Endoscopy and Minimal Invasive Surgery; Korean Society of Maternal Fetal Medicine; Korean Society of Ultrasound in Obstetrics and Gynecology; Korean Urogynecologic Society 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4958672/
https://www.ncbi.nlm.nih.gov/pubmed/27462593
http://dx.doi.org/10.5468/ogs.2016.59.4.269
_version_ 1782444329063677952
author Oh, Jinju
Lee, Hyun Joo
Lee, Tae Sung
Kim, Ju Hyun
Koh, Suk Bong
Choi, Youn Seok
author_facet Oh, Jinju
Lee, Hyun Joo
Lee, Tae Sung
Kim, Ju Hyun
Koh, Suk Bong
Choi, Youn Seok
author_sort Oh, Jinju
collection PubMed
description OBJECTIVE: The objective of this study was to evaluate the clinical benefits of routine squamous cell carcinoma antigen (SCC-Ag) monitoring of patients with locally advanced cervical squamous cell carcinoma treated with radiation or chemoradiation. METHODS: A total of 53 patients with recurrent cervical squamous cell carcinoma treated with radiotherapy or chemoradiation were enrolled in this study. A retrospective review of medical records was conducted. The role of routine monitoring of serum SCC-Ag was evaluated in terms of cost effectiveness and effect on survival after diagnosis of recurrence. RESULTS: Serum SCC-Ag abnormality (≥2.5 ng/mL) was observed in 62.3% of patients when recurrent disease was diagnosed. The first indicator of relapse was abnormal serum SCC-Ag level in 21 patients (39.6%), 10 of whom had asymptomatic recurrent disease amenable to salvage therapy. Adding SCC-Ag measurement to the basic follow up protocol improved the sensitivity for detecting recurrence (The sensitivity of the basic protocol vs. addition of SCC-Ag: 49.1% vs. 88.7%, P<0.001). Twenty-three patients who were candidates for salvage therapy with curative intent showed better survival compared with those who were not candidates for therapy (5-year survival: 36.6% vs. 0%, P=0.012). CONCLUSION: Surveillance with routine serum SCC-Ag monitoring can better detect asymptomatic recurrent disease that is potentially amenable to salvage therapy with curative intent. Early diagnosis of recurrent disease that can be treated with salvage therapy may lead to better survival.
format Online
Article
Text
id pubmed-4958672
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Korean Society of Obstetrics and Gynecology; Korean Society of Contraception and Reproductive Health; Korean Society of Gynecologic Endocrinology; Korean Society of Gynecologic Endoscopy and Minimal Invasive Surgery; Korean Society of Maternal Fetal Medicine; Korean Society of Ultrasound in Obstetrics and Gynecology; Korean Urogynecologic Society
record_format MEDLINE/PubMed
spelling pubmed-49586722016-07-26 Clinical value of routine serum squamous cell carcinoma antigen in follow-up of patients with locally advanced cervical cancer treated with radiation or chemoradiation Oh, Jinju Lee, Hyun Joo Lee, Tae Sung Kim, Ju Hyun Koh, Suk Bong Choi, Youn Seok Obstet Gynecol Sci Original Article OBJECTIVE: The objective of this study was to evaluate the clinical benefits of routine squamous cell carcinoma antigen (SCC-Ag) monitoring of patients with locally advanced cervical squamous cell carcinoma treated with radiation or chemoradiation. METHODS: A total of 53 patients with recurrent cervical squamous cell carcinoma treated with radiotherapy or chemoradiation were enrolled in this study. A retrospective review of medical records was conducted. The role of routine monitoring of serum SCC-Ag was evaluated in terms of cost effectiveness and effect on survival after diagnosis of recurrence. RESULTS: Serum SCC-Ag abnormality (≥2.5 ng/mL) was observed in 62.3% of patients when recurrent disease was diagnosed. The first indicator of relapse was abnormal serum SCC-Ag level in 21 patients (39.6%), 10 of whom had asymptomatic recurrent disease amenable to salvage therapy. Adding SCC-Ag measurement to the basic follow up protocol improved the sensitivity for detecting recurrence (The sensitivity of the basic protocol vs. addition of SCC-Ag: 49.1% vs. 88.7%, P<0.001). Twenty-three patients who were candidates for salvage therapy with curative intent showed better survival compared with those who were not candidates for therapy (5-year survival: 36.6% vs. 0%, P=0.012). CONCLUSION: Surveillance with routine serum SCC-Ag monitoring can better detect asymptomatic recurrent disease that is potentially amenable to salvage therapy with curative intent. Early diagnosis of recurrent disease that can be treated with salvage therapy may lead to better survival. Korean Society of Obstetrics and Gynecology; Korean Society of Contraception and Reproductive Health; Korean Society of Gynecologic Endocrinology; Korean Society of Gynecologic Endoscopy and Minimal Invasive Surgery; Korean Society of Maternal Fetal Medicine; Korean Society of Ultrasound in Obstetrics and Gynecology; Korean Urogynecologic Society 2016-07 2016-07-13 /pmc/articles/PMC4958672/ /pubmed/27462593 http://dx.doi.org/10.5468/ogs.2016.59.4.269 Text en Copyright © 2016 Korean Society of Obstetrics and Gynecology http://creativecommons.org/licenses/by-nc/3.0/ Articles published in Obstet Gynecol Sci are open-access, distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Oh, Jinju
Lee, Hyun Joo
Lee, Tae Sung
Kim, Ju Hyun
Koh, Suk Bong
Choi, Youn Seok
Clinical value of routine serum squamous cell carcinoma antigen in follow-up of patients with locally advanced cervical cancer treated with radiation or chemoradiation
title Clinical value of routine serum squamous cell carcinoma antigen in follow-up of patients with locally advanced cervical cancer treated with radiation or chemoradiation
title_full Clinical value of routine serum squamous cell carcinoma antigen in follow-up of patients with locally advanced cervical cancer treated with radiation or chemoradiation
title_fullStr Clinical value of routine serum squamous cell carcinoma antigen in follow-up of patients with locally advanced cervical cancer treated with radiation or chemoradiation
title_full_unstemmed Clinical value of routine serum squamous cell carcinoma antigen in follow-up of patients with locally advanced cervical cancer treated with radiation or chemoradiation
title_short Clinical value of routine serum squamous cell carcinoma antigen in follow-up of patients with locally advanced cervical cancer treated with radiation or chemoradiation
title_sort clinical value of routine serum squamous cell carcinoma antigen in follow-up of patients with locally advanced cervical cancer treated with radiation or chemoradiation
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4958672/
https://www.ncbi.nlm.nih.gov/pubmed/27462593
http://dx.doi.org/10.5468/ogs.2016.59.4.269
work_keys_str_mv AT ohjinju clinicalvalueofroutineserumsquamouscellcarcinomaantigeninfollowupofpatientswithlocallyadvancedcervicalcancertreatedwithradiationorchemoradiation
AT leehyunjoo clinicalvalueofroutineserumsquamouscellcarcinomaantigeninfollowupofpatientswithlocallyadvancedcervicalcancertreatedwithradiationorchemoradiation
AT leetaesung clinicalvalueofroutineserumsquamouscellcarcinomaantigeninfollowupofpatientswithlocallyadvancedcervicalcancertreatedwithradiationorchemoradiation
AT kimjuhyun clinicalvalueofroutineserumsquamouscellcarcinomaantigeninfollowupofpatientswithlocallyadvancedcervicalcancertreatedwithradiationorchemoradiation
AT kohsukbong clinicalvalueofroutineserumsquamouscellcarcinomaantigeninfollowupofpatientswithlocallyadvancedcervicalcancertreatedwithradiationorchemoradiation
AT choiyounseok clinicalvalueofroutineserumsquamouscellcarcinomaantigeninfollowupofpatientswithlocallyadvancedcervicalcancertreatedwithradiationorchemoradiation